Pharmaceuticals, Biotechnology and Life Sciences
Resolution of middle ear effusion in 56% of OP0201 vs. 38% of placebo patients (p=0.07) Company engages financial advisors to…
The company reported a net loss of $8.2 million, or $0.47 per share, for the three months ended March 31, 2020, compared to a net loss of $4.9 million, or $0.52 per share, for the same period in 2019. The company had $11.8 million in cash and cash equivalents as of March 31, 2020.
IRVINE, Calif.–(BUSINESS WIRE)–$NVUS–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of…
Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile